Full Text View
Tabular View
No Study Results Posted
Related Studies
Depression Outcomes Study of Exercise (DOSE)
This study is currently recruiting participants.
Verified by National Institute of Mental Health (NIMH), August 2009
First Received: August 20, 2009   Last Updated: November 3, 2009   History of Changes
Sponsor: Klein Buendel, Inc.
Collaborator: University of Colorado at Denver and Health Sciences Center
Information provided by: National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier: NCT00964054
  Purpose

This pilot study may yield important research findings on how to adapt exercise treatment for depression among adolescents. Potential public health benefits from this study include a reduction of adolescent depression and problems associated with untreated depression in young adults including suicide, substance abuse, cigarette smoking, teen pregnancy, impaired psychosocial functioning and school failure. In addition, because this study prescribes physical activity as a treatment for depression, additional public health benefits may include a reduction in chronic diseases such as obesity, diabetes and heart disease, all of which are associated with sedentary behavior.


Condition Intervention Phase
Major Depressive Disorder (MDD)
Other: Public Health Dose of Exercise (PHD)
Other: Low Dose Exercise (LD)
Phase I

Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Efficacy Study
Official Title: Adapting Exercise Treatment for Depression to Adolescents: A Pilot Study

Resource links provided by NLM:


Further study details as provided by National Institute of Mental Health (NIMH):

Primary Outcome Measures:
  • Child Depression Rating Scale-Revised (CDRS-R) [ Time Frame: repeated measures, 12-weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Beck Depression Inventory (BDI) [ Time Frame: repeated measures, 12 weeks ] [ Designated as safety issue: Yes ]
  • Clinical Global Impression Scale (CGI) [ Time Frame: baseline, 6weeks and 12 weeks ] [ Designated as safety issue: No ]
  • Clinical Global Assessment Scale (CGAS) [ Time Frame: baseline, 6 weeks and 12 weeks ] [ Designated as safety issue: No ]
  • Health of the Nation Outcomes Scale for Children and Adolescents (HoNOSCA) [ Time Frame: baseline, 6 weeks and 12 weeks ] [ Designated as safety issue: No ]
  • The Multidimensional Anxiety Scale for Children (MASC) [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Adolescent Stress Questionnaire (ASQ) [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Perceived Criticism (PC) [ Time Frame: baseline, 6 weeks and 12 weeks ] [ Designated as safety issue: No ]
  • General Functioning sub scale of Family Assessment Device (GF FAD) [ Time Frame: baseline, 6 weeks and 12 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: September 2009
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Public Health Dose of Exercise (PHD): Experimental
17.5 kcal per kilogram per week
Other: Public Health Dose of Exercise (PHD)
17.5 kcal per kilogram per week
Low Dose Exercise (LD): Active Comparator
7.0 kcal per kilogram per week
Other: Low Dose Exercise (LD)
7.0 kcal per kilogram per week

Detailed Description:

Adolescent depression is a major public health problem in the United States and throughout the world. Major depressive disorder (MDD) in adolescence is common with point prevalence rates of 3% to 9%. In the U.S., it is estimated that by the time adolescents reach the age of 17, 14% will have experienced at least one episode of major depressive disorder. Effective treatments of adolescent depression are clearly needed despite the fact that in the past 10-15 years, there has been a dramatic increase in studies of the efficacy of medications, primarily the selective serotonin reuptake inhibitors (SSRIs) and of cognitive behavioral therapy (CBT). Medications and CBT rarely result in complete and lasting remission of symptoms, and residual symptoms are associated with a high rate of relapse. In most studies, a positive response is defined as a 30-50% improvement in symptoms and/or a global rating that the subject is much or very much improved. In adults, exercise has been used as a mono-therapy and as an augmentation therapy with antidepressant medication. Our recently completed randomized trial of exercise treatment in adults found response and remission rates of 46% and 42%, in those randomized to a public health dose of exercise. In adolescents, data on the use of exercise to treat MDD is relatively sparse. A 2006 Cochrane review of exercise to prevent and treat depression in adolescents found a small effect size in support of exercise, but the conclusion is based on evidence from a small number of randomized clinical trials of low methodological quality. In this exploratory R34, the specific aims of this application are to: 1) Develop a detailed Manual of Procedures (MOP) to conduct an acute-phase randomized trial of exercise to treat adolescent depression; 2) Develop estimates of recruitment yield from tests of various recruitment strategies; and, 3) Pilot test trial methodologies in (n=40) adolescents diagnosed with depression to ascertain estimates of treatment effect sizes, adherence and drop-out rates. To achieve these aims, the project is organized into 3 phases. Phase I will be the development of the first draft MOP that will adapt procedures developed from a previous trial examining two doses of exercise in treatment of adult MDD. Phase II will test specific recruitment methodologies to determine recruitment yields for each strategy and will pilot test screening procedures developed in Phase I. Phase III will be a pilot test of the intervention and will include development of baseline and outcome measures of exercise and depression; development and implementation of the experimental exercise treatment; and determination of the effects of exercise on depressive symptoms. Following the pilot study, we will finalize all procedures for the MOP and obtain estimates of effect sizes, adherence and drop out rates. These data will allow us to specify all study procedures necessary to meet standards of high methodological quality for a future, larger-scale, controlled study of exercise in depressed youth and will provide us with needed experience.

  Eligibility

Ages Eligible for Study:   12 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Primary Diagnosis of DSM-IV Major Depression Disorder (MDD)
  • Child Depression Rating Scale Revised > or = 40 at final screen
  • 12 to 17 years of age
  • Free of psychotropic medication (except stimulants for ADHD)
  • Physically capable of exercise according to AHA and ACSM standards
  • Able to pass illicit drug screen
  • Perform < 30 minutes per day of moderate to vigorous physical activity
  • Parental consent and participant assent
  • Denver resident

Exclusion Criteria:

  • Chronic disease that would limit exercise
  • Other psychiatric illness
  • Suicidal or homicidal
  • Concurrent psychotropic medication (except ADHD stimulant) or psychotherapy
  • Two previous failed SSRI trials or a failed trial of CBT
  • Current pregnancy or breastfeeding
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00964054

Contacts
Contact: Jennifer S Jewell, MSPH 303-565-4346 jjewell@kleinbuendel.com
Contact: Andrea L Dunn, PhD 303-565-4342 adunn@kleinbuendel.com

Locations
United States, Colorado
Klein Buendel, Inc Recruiting
Golden, Colorado, United States, 80401
Principal Investigator: Andrea L Dunn, PhD            
University of Colorado at Denver Health Sciences Center Recruiting
Aurora, Colorado, United States, 80045
Principal Investigator: Philippe Weintraub, MD            
Sponsors and Collaborators
Klein Buendel, Inc.
University of Colorado at Denver and Health Sciences Center
Investigators
Principal Investigator: Andrea L Dunn, PhD Klein Buendel, Inc.
Principal Investigator: Philippe Weintraub, MD University of Colorado at Denver Health Sciences Center
  More Information

No publications provided

Responsible Party: Klein Buendel, Inc. ( Andrea L. Dunn, Senior Research Scientist )
Study ID Numbers: R34 MH082153, MH082153, DSIR 84-CTS
Study First Received: August 20, 2009
Last Updated: November 3, 2009
ClinicalTrials.gov Identifier: NCT00964054     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Institute of Mental Health (NIMH):
adolescents
exercise
depression
dose response
pilot study

Additional relevant MeSH terms:
Depression
Mental Disorders
Mood Disorders
Depressive Disorder, Major
Depressive Disorder
Behavioral Symptoms

ClinicalTrials.gov processed this record on November 20, 2009